The influence of laparoscopic adjustable gastric banding and laparoscopic sleeve gastrectomy on weight loss, plasma Ghrelin, insulin, glucose and lipids

Folia Histochemica et Cytobiologica

Volumn 50, Issue 2, 2012, Pages 292-303

  Hady, Hady Razak ^a   Golaszewski, Pawel ^a   Zbucki, Robert Lukasz ^a   Dadan, Jacek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

LAGB; LSG; Metabolic parameters; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UREA; URIC ACID;

ADULT; ARTICLE; BODY MASS; COMORBIDITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME BLOOD LEVEL; FEMALE; GASTRIC BANDING; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; SLEEP APNEA SYNDROME; SLEEVE GASTRECTOMY; UPREGULATION; WEIGHT REDUCTION;

EID: 84863874545     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0039     Document Type: Article

References (74)

1. Grundy SM. Multifactorial causation of obesity: implications for prevention. Am J Clin Nutr. 1998;67(Suppl):563S-572S.
2. Hill JO, Peters JC. Environmental contributions to the obesity epidemic. Science. 1998;280:1371-1374.
3. Hady RH, Zbucki RL, Luba ME et al. Obesity as social disease and the influence of environmental factors on BMI in own material. Adv Clin Exp Med. 2010;19:369-378.
4. Ogden CL, Yanovsky SZ, Carroll MD et al. The epidemiology of obesity. Gastroenterology. 2007;132:2087-2102.
5. Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol. 2006;35:93-99.
6. Wylezol M, Pasnik K, Dabrowiecki S et al. Polish recommendations for bariatric surgery. Videosurgery and other miniinvasive techniques. 2009;4(Suppl 1):S5-S8.
7. Milewicz A, Jedrzejuk D, Lwow F et al. Prevelance of obesity in Poland. Obes Rev. 2005;6:113-114.
8. Kojima M, Hosoda H, Date Y et al. Ghrelin is a growthhormone releasing acylated peptide from stomach. Nature. 1999;402:656-660.
9. Date Y, Kojima M, Hosoda H et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in distinct endocrine cell type in gastrointenstinal tracts of rats and humans. Endocrinol. 2000;141:4255-4261.
10. Muccioli G, Tschop M, Papotti M et al. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol. 2002;440:235-254.
11. Rigamonti AE, Pincelli AI, Corra B et al. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J Endocrinol. 2002;175:1-5.
12. Broglio F, Arvat E, Benso A et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86:5083-5086.
13. Castańeda TR, Tong J, Datta R et al. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol. 2010;31:44-60.
14. Dadan J, Hady RH, Zbucki RL et al. The activity of gastric ghrelin positive cells in obese patients treated surgically. Folia Histochem Cytobiol. 2009;47:307-313.
15. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-887.
16. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization; 1999. Available at: http://whqlibdoc.who.int/hq/1999//WHO_NCD_NCS_99.2.pdf.
17. Grundy SM, Brewer HB, Cleeman JI et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109;433-438.
18. Iannelli A, Dainese R, Piche T et al. Laparoscopic sleeve gastrectomy for morbid obesity. World J Gastroenterol. 2008; 14:821-827.
19. Morino M, Toppino M, Garrone C et al. Laparoscopic adjustable silicone gastric banding for the treatment of morbid obesity. Br J Surg. 1994;81:1169-1170.
20. Marceau P, Hould FS, Simard S et al. Biliopancreatic diversion with duodenal switch. World J Surg. 1998;22:947-954.
21. Johnston D, Dachtler J, Sue-Ling HM et al. The Magenstrasse and Mill operation for morbid obesity. Obes Surg. 2003;13:10-16.
22. Buchwald H, Oien D. Metabolic/bariatric surgery worldwide 2008. Obes Surg. 2009;19:1605-1611.
23. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-1495.
24. Deitel M, Gawdat K, Melissas J. Reporting weight loss 2007. Obes Surg. 2007;17:565-568.
25. Klingler A. Statistical methods in surgical research - a practical guide. Eur Surg. 2004;36:80-84.
26. Steinbrook R. Surgery for severe obesity. N Eng J Med. 2004; 350:1075-1079.
27. Tice JA, Karliner L, Walsh J et al. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med. 2008;121:885-893.
28. Pérez-Romero N, Serra A, Granada ML et al. Effects of two variants of Roux-en-Y gastric bypass on metabolism behaviour: focus on plasma ghrelin concentrations over a 2-year follow-up. Obes Surg. 2010;20:600-690.
29. Frezza EE, Wozniak SE, Gee L et al. Is there any role of resecting the stomach to ameliorate weight loss and sugar control in morbidly obese diabetic patients? Obes Surg. 2009; 19:1139-1142.
30. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292: 1724-1737.
31. Nocca D. Laparoscopic adjustable gastric banding and laparoscopic sleeve gastrectomy: which has a place in the treatment of diabetes in morbidly obese patients? Diabetes Metab. 2009;35:524-527.
32. Armstrong J, O'Malley SP. Outcomes of sleeve gastrectomy for morbid obesity: a safe and effective procedure? Int J Surg. 2010;8:69-71.
33. Karamanakos SN, Vagenas K, Kalfarentzos F et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy. Ann Surg. 2008;247:401-407.
34. Ponce J, Paynter S, Fromm R. Laparoscopic adjustable gastric banding: 1,014 consecutive cases. J Am Coll Surg. 2005; 201:529-535.
35. de Jong JR, van Ramshorst B, Gooszen HG et al. Weight loss after laparoscopic adjustable gastric banding is not caused by altered gastric emptying. Obes Surg. 2009;19:287-292.
36. Himpens J, Dapri G, Cadičre GB. A prospective randomizeds between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg. 2006;16:1450-1456.
37. Shi X, Karmali S, Sharma AM et al. A review of laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2010;20: 1171-1177.
38. Sjöström L, Narbro K, Sjöström CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-752.
39. Himpens J, Dobbeleir J, Peeters G. Long-term results of laparoscopic sleeve gastrectomy for obesity. Ann Surg. 2010;252: 319-324.
40. Gagner M, Deitel M, Kalberer TL et al. The second international consensus summit for sleeve gastrectomy, March 19- -21, 2009. Surg Obes Relat Dis. 2009;5:476-485.
41. Schindler K, Prager G, Ballaban T et al. Impact of laparoscopic adjustable gastric banding on plasma ghrelin, eating behaviour and body weight. Eur J Clin Inv. 2004;34:549-554.
42. De Vriese C, Delporte C. Ghrelin: A new peptide regulating growth hormone release and food intake. Int J Biochem Cell Biol. 2008;40:1420-1424.
43. Fruhbeck G, Diez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Eng J Med. 2004;350:308-309.
44. Wölnerhanssen BK, Peters T, Kern B et al. Predictors of outcome in treatment of morbid obesity by laparoscopic adjustable gastric banding: results of a prospective study of 380 patients. Surg Obes Relat Dis. 2008;4:500-506.
45. Langer FB, Reza Hoda MA, Bohdjalian A et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg. 2005;15:1024-1029.
46. Bohdjalian A, Langer FB, Shakeri-Leidenmühler S et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010; 20:535-540.
47. Sammour T, Hill AG, Singh P et al. Laparoscopic sleeve gastrectomy as a single-stage bariatric procedure. Obes Surg. 2010; 20:271-275.
48. Basso N, Casella G, Rizzello M et al. Laparoscopic sleeve gastrectomy as first stage or definitive intent in 300 consecutive cases. Surg Endosc. 2010;25:444-449.
49. Tymitz K, Engel A, McDonough S et al. Changes in ghrelin levels following bariatric surgery: review of the literature. Obes Surg. 2011;21:125-130.
50. Saad MF, Bernaba B, Hwu CM et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab. 2002;87: 3997-4000.
51. McLaughlin T, Abbasi F, Lamendola C et al. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrin Metabol. 2004;89:1630-1635.
52. Spanakis E, Gragnoli C. Bariatric surgery, safety and type 2 diabetes. Obes Surg. 2009;19:363-368.
53. Kim SH, Reaven GM. Insulin resistance and hyperinsulinemia. Diabetes Care. 2008;31:1433-1438.
54. Silecchia G, Boru C, Pecchia A et al. Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on comorbidities in super-obese high-risk patients. Obes Surg. 2006;16:1138-1144.
55. Rosenthal R, Li X, Samuel S et al. Effect of sleeve gastrectomy on patients with diabetes mellitus. Obes Relat Dis. 2009; 5:429-434.
56. Rizzello M, Abbatini F, Casella G et al. Early postoperative insulin-resistance changes after sleeve gastrectomy. Obes Surg. 2010;20:50-55.
57. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and metaanalysis. Am J Med. 2009;122:248-256.
58. Omana JJ, Nguyen SQ, Herron D et al. Comparison of comorbidity resolution and improvement between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding. Surg Endosc. 2010;24:2513-2517.
59. Parikh M, Ayoung-Chee P, Romanos E et al. Comparison of rates of resolution of diabetes mellitus after gastric banding, gastric bypass, and biliopancreatic diversion. J Am Coll Surg. 2007;205:631-635.
60. Vidal J, Ibarzabal A, Nicolau J et al. Short-term effects of sleeve gastrectomy on type 2 diabetes mellitus in severely obese subjects. Obes Surg. 2007;17:1069-1074.
61. Fried M, Ribaric G, Buchwald JN et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI < 35 kg/m2: An integrative review of early studies. Obes Surg. 2010;20:776-790.
62. Peterli R, Wölnerhanssen B, Peters T et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy. A prospective randomized trial. Ann Surg. 2009;250:234-241.
63. Lee WJ, Lee YC, Ser KH Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures. Obes Surg. 2008;18:1119-1125.
64. Ballantyne GH, Wasilewski A, Saunders JK. The surgical treatment of type II diabetes mellitus: changes in HOMA insulin resistance in the first year following laparoscopic Rouxen- Y gastric bypass (LRYGB) and laparoscopic adjustable gastric banding (LAGB). Obes Surg. 2009;19:1297-1303.
65. Batsis JA, Romero-Corral A, Collazo-Clavell M et al. The effect of bariatric surgery on the metabolic syndrome: a population- based, long-term controlled study. Mayo Clin Proc. 2008;83:897-907.
66. Cunneen SA. Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding. Surg Obes Relat Dis. 2008;4(Suppl 1):S47-S55.
67. Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.
68. Vidal J, Ibarzabal A, Romero F et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008;18:1077-1082.
69. Iannelli A, Anty R, Schneck AS et al. Inflammation, insulin resistance, lipid disturbances, anthropometrics, and metabolic syndrome in morbidly obese patients: a case control study comparing laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy. Surgery. 2010;149:364-370.
70. Chen PH, Chen JD, Lin YC. A better parameter in predicting insulin resistance: obesity plus elevated alanine aminotransferase. World J Gastroenterol. 2009;28; 15: 5598-5603.
71. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology. 2007;132:2253-2271.
72. Magee CJ, Barry J, Arumugasamy M et al. Laparoscopic sleeve gastrectomy for high-risk patients: weight loss and comorbidity improvement - short-term results. Obes Surg. Published online 10 July 2010.
73. Agrawal S, Dessel E, Akin F et al. Laparoscopic adjustable banded sleeve gastrectomy as a primary procedure for the super-super obese (Body mass index > 60 kg/m2). Obes Surg. 2010;20:1161-1163.
74. Miguel G, Azevedo J, Neto C et al. Glucose homeostasis and weight loss in morbidly obese patients undergoing banded sleeve gastrectomy: a prospective clinical study. Clinics. 2009; 64:1093-1099.